Highest-materiality recent filing
CNBX Pharmaceuticals enters convertible note with $55K initial, up to $850K, 35% discount conversion
Issue Date Jan 23, 2025; maturity Oct 30, 2025; 10% interest, 9% OID, default interest 22%.
CNBX Pharma effects 1:120 reverse split and cuts authorized preferred to 5M shares
Reverse stock split of 1:120 effective May 12, 2022; par value unchanged.
Cannabics defaults on $1.375M note, obtains forbearance; issues $280K demand note
Forbearance with institutional investor on $1.375M Senior Secured Note due Dec 21, 2021; forbearance through May 7, 2022.
Company defaulted on $1,375,000 Senior Secured Convertible Promissory Note due December 21, 2021.
On January 31 st , 2023, Dr. Inbar Maymon Pomeranchik resigned from her position as a Director and Board Member.
Also on January 31 st , 2023, Gil Feiler also presented his resignation as a Director and Board Member.
On December 25th, 2022, Shaul Yemal resigned his position as Director and Board Member.
Dr. Sanja Goldberg was appointed as the Company’s new Chief Technology Officer on July 24 th , 2022.
Chief Technology Officer Dr. Eyal Ballan has resigned his position as CTO and his employment with the Company has ended effective July 20 th , 2022.
On November 16 th , 2021, the Board of Directors (the “Board”) increased the size of the Board to five (5) members, and appointed Mr. Shaul Yemal to the Board as an Independent Director and as a member of the Audit Committee.
On September 5 rd , 2021, the Board of Directors nominated fellow Director Mr. Gabriel Yariv as Executive Chairman of the Board.
On July 15th, 2021, the Board of Directors appointed Dr. Gil Feiler as an Independent Board Member
On July 1 st , 2021, the Board of Directors appointed Dr. Inbar Maymon Pomeranchik as an Independent Board Member.
Max materiality 0.70 · Median 0.50 · Most common event leadership